The FDA has granted breakthrough therapy designation (BTD) for bezuclastinib in combination with sunitinib (Sutent) for the ...
Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in ...
The FDA granted breakthrough therapy designation to bezuclastinib plus Sutent for patients with gastrointestinal stromal ...
A recent study offering a comprehensive view of the genome and transcriptome of gastrointestinal stromal tumors (GISTs) has introduced a new, multi-omics-based molecular classification of these tumors ...
GISTs originate from interstitial cells of Cajal and are staged by size, location, mitotic rate, and genetic mutations, influencing treatment strategies. Diagnosis involves imaging, endoscopy, biopsy, ...
A recent study offering a comprehensive view of the genome and transcriptome of gastrointestinal stromal tumors (GISTs) has introduced a new, multi-omics-based molecular classification of these tumors ...
Gastrointestinal stromal tumors (GISTs) represent a rare tumor entity that occurs in the muscular layer of the digestive tract. These tumors commonly metastasize to the liver and peritoneum, and ...
These study authors hope their findings will inform future research on gastrointestinal stromal tumors (GIST) and close care gaps for minority patient populations. Unfavorable trends in the diagnosis ...
GSK plc (NYSE:GSK) agreed to acquire IDRx, Inc., a biopharmaceutical company focused on precision therapeutics for gastrointestinal stromal tumors (GIST), for $1 billion. Under the agreement, GSK ...
A recent study offering a comprehensive view of the genome and transcriptome of gastrointestinal stromal tumors (GISTs) has introduced a new, multi-omics-based molecular classification of these tumors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results